ARDX
NASDAQ · Biotechnology
Ardelyx Inc
$2.93
+0.05 (+1.74%)
Financial Highlights (FY 2026)
Revenue
441.02M
Net Income
-66,704,846
Gross Margin
90.3%
Profit Margin
-15.1%
Rev Growth
+98.4%
D/E Ratio
1.21
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 90.3% | 90.3% | 66.0% | 66.0% |
| Operating Margin | -10.1% | -9.1% | -4.0% | -3.7% |
| Profit Margin | -15.1% | -14.4% | -4.1% | -4.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 441.02M | 222.29M | 556.78M | 692.55M |
| Gross Profit | 398.20M | 200.70M | 367.51M | 457.13M |
| Operating Income | -44,366,536 | -20,125,948 | -22,163,280 | -25,304,268 |
| Net Income | -66,704,846 | -30,259,254 | -22,621,785 | -27,854,629 |
| Gross Margin | 90.3% | 90.3% | 66.0% | 66.0% |
| Operating Margin | -10.1% | -9.1% | -4.0% | -3.7% |
| Profit Margin | -15.1% | -14.4% | -4.1% | -4.0% |
| Rev Growth | +98.4% | +98.4% | +16.2% | +24.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 206.13M | 206.13M | 237.65M | 275.35M |
| Total Equity | 169.67M | 169.67M | 638.29M | 606.79M |
| D/E Ratio | 1.21 | 1.21 | 0.37 | 0.45 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -41,051,143 | -19,656,545 | -31,484,723 | -42,657,512 |
| Free Cash Flow | — | — | -21,445,059 | -24,067,993 |